The global rheumatoid arthritis drugs market, valued at US$31.27 billion in 2024, is projected to reach US$56.62 billion by 2033 at a 6.8% CAGR. Explore drivers like rising RA prevalence, early diagnosis advancements, and biologics innovations (TNF inhibitors, IL-6 blockers) amid JAK inhibitors like Upadacitinib and improved access in emerging markets. https://au.finance.yahoo.com/news/rheumatoid-arthritis-drugs-market-size-155000726.html